Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AIT Austrian Institute of Technology GmbH | OTHER |
| Medical University of Graz | OTHER |
| UMIT Tirol | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The Austrian Digital Heart Study is a population-based, siteless, randomized, controlled digital trial testing whether a smartphone-based atrial fibrillation screening and management pathway reduces stroke hospitalizations compared with usual care. Adults aged 65 years or older in Austria are randomized to either a digital intervention using the 'Pulskontrolle' app or to usual care. The intervention includes smartphone-camera photoplethysmography for atrial fibrillation screening, confirmatory 7-day ECG patch monitoring in case of suspected atrial fibrillation, and digital education and management support. The primary outcome is hospitalization for stroke of any type within 48 months.
Atrial fibrillation is common in older adults, often remains undetected, and is a major risk factor for stroke, heart failure, hospitalization, and death. Digital screening using smartphone-based photoplethysmography provides substantial benefits in detecting atrial fibrillation compared to usual care, but it remains unclear whether such screening improves clinical outcomes.
The Austrian Digital Heart Study tests a brand-independent digital atrial fibrillation screening and management pathway embedded in the Austrian public health-care system. Participants randomized to the intervention arm use the 'Pulskontrolle' smartphone application for repeated photoplethysmographic pulse-wave (PPG) recordings. If atrial fibrillation is suspected, confirmatory 7-day ECG patch monitoring is initiated. Participants with positive PPG receive structured digital information, telehealth support, and guideline-oriented management recommendations.
The control arm receives usual care without active app-based atrial fibrillation screening. The primary endpoint is hospitalization for stroke of any type within 48 months after randomization. Secondary outcomes include mortality, cardiovascular morbidity, bleeding, atrial fibrillation-related outcomes, health-care utilization, and health-economic endpoints.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Digital atrial fibrillation screening and management | Experimental | Participants assigned to the experimental arm are offered access to the 'Pulskontrolle' app. The app supports smartphone-camera photoplethysmography recordings for atrial fibrillation screening, digital education, and atrial fibrillation management support. Participants with suspected atrial fibrillation undergo confirmatory 7-day ECG patch monitoring. Confirmed atrial fibrillation triggers structured digital and telehealth-supported guidance according to guideline-oriented care pathways. |
|
| Usual care | No Intervention | Participants assigned to the control arm receive usual care. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Smartphone-based digital atrial fibrillation screening and management pathway | Device | Participants randomized to the digital intervention arm receive access to a smartphone-based atrial fibrillation screening and management pathway. The intervention includes photoplethysmography-based pulse wave measurements using a CE-certified smartphone application, followed by confirmatory 7-day ECG patch monitoring in participants with abnormal findings suggestive of atrial fibrillation. Participants with suspected or confirmed atrial fibrillation receive structured digital information, adherence support, and the option of telehealth guidance to facilitate guideline-oriented care. Treatment decisions remain the responsibility of the participant's usual treating physician. |
| Measure | Description | Time Frame |
|---|---|---|
| Hospitalization for stroke of any type (ischemic or hemorrhagic) | Up to 48 months |
| Measure | Description | Time Frame |
|---|---|---|
| Hospitalization for Ischemic stroke | Up to 48 months | |
| Hospitalization for Hemorrhagic stroke | Up to 48 months | |
| All-cause mortality |
Not provided
Inclusion Criteria
a) Currently treated with oral anticoagulation b) Cardiac implanted electronic device (CIED)
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sebastian J Reinstadler, MD, PhD | Contact | +4351250425621 | sebastian-johannes.reinstadler@i-med.ac.at | |
| Michael Schreinlechner, MD | Contact | Michael.Schreinlechner@i-med.ac.at |
| Name | Affiliation | Role |
|---|---|---|
| Axel Bauer | Medical University Innsbruck | Study Chair |
| Sebastian J Reinstadler, MD, PhD | Medical University Innsbruck | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Internal Medicine III, Medical University Innsbruck | Recruiting | Innsbruck | Tyrol | 6020 | Austria |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| D020521 | Stroke |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Up to 48 months |
| Cardiovascular mortality | Up to 48 months |
| Hospitalization for heart failure | Up to 48 months |
| The combination of hospitalization for stroke, hospitalization for heart failure and cardiovascular death. | Up to 48 months |
| Hospitalization for bleeding | up to 48 months |
| Fatal bleeding | up to 48 months |
| Cost and incremental cost effectiveness ratio | Up to 48 months |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |